Question 1

Am I eligible for this trial based on my previous treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL clinical trial (NCT04404283). Contact the study team or your healthcare provider for specific answers.

Question 2

How does brentuximab vedotin compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL clinical trial (NCT04404283). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL clinical trial (NCT04404283). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL clinical trial (NCT04404283). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL clinical trial (NCT04404283). Contact the study team or your healthcare provider for specific answers.

Question 6

Will I receive a placebo, and how will that affect my treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL clinical trial (NCT04404283). Contact the study team or your healthcare provider for specific answers.

What this study is about